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Purpose: The association between survivor motor neuron (SMN) gene deletion 
and spinal muscular atrophy suggests that sporadic amyotrophic lateral sclerosis 
(sALS) may be related to SMN deletion. We examined the association between the 
SMN genotype and susceptibility to and severity of sALS. Materials and Meth-
ods: We genotyped the copy number of SMN1 and SMN2 in 25 patients diagnosed 
with sporadic ALS and 100 healthy subjects in a Korean population. Onset age 
and medical research council (MRC) scale were compared among patients accord-
ing to SMN1 : SMN2 genotypes. Results: There was a significantly higher inci-
dence of homozygous deletion of SMN2 (SMN1 : SMN2 genotype, 2 : 0) in sALS 
patients (20%) than in the normal controls (2%) (p<0.001). The onset age for patients 
with homozygous deletion of SMN2 (2 : 0) was significantly younger (34±15.38 
years) than that of patients with 2 : 1, 2 : 2 and 2 : 3 of the SMN1 : SMN2 genotype 
(59.5±5.09; 52.69±16.46 and 50±0.00 years) (p=0.049). The ratio of patients with 
an MRC scale above G4- was smaller in the 2 : 0 genotype (40%) than in the 2 : 1, 
2 : 2 and 2 : 3 genotypes (83.3%, 100% and 100%) (p=0.02). Conclusion: The ho-
mozygous SMN2 deletion (2 : 0) was statistically more frequent and associated 
with earlier onset age and lower MRC scale in Korean sALS patients. These sug-
gest that SMN2 deletion may be one of the factors associated with susceptibility to 
and severity of sALS in a Korean population.
Key Words:   SMN1, SMN2, amyotrophic lateral sclerosis, age of onset, disease 
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a fatal disease characterized by progressive 
degeneration of upper and lower motor neurons resulting in ventilatory failure and 
ultimately death within an average of 2-3 years of onset. It is the most common 
adult-onset disease with an incidence of two in 100,000 and a lifetime risk of one 
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consent and blood samples from all subjects. This study 
was approved by the Institutional Review Board of Yonsei 
University Health System and informed consent was ob-
tained in accordance with the Declaration of Helsinki.
DNA analysis
DNA was extracted from the peripheral blood of each sub-
ject using the Easy-DNA kit (Invitrogen Life Technologies 
Corp., Carlsbad, CA, USA). A spectrophotometer was used 
to determine the concentration of the DNA samples. Using 
the commercially available SALSA MLPA KIT P021 SMA 
(MRC-Holland, Amsterdam, Netherlands), we genotyped 
the copy number of SMN1 and SMN2 in each subject. The 
kit contains a probe mixture for SMN1 exons 7 and 8, SMN2 
exons 7 and 8, SMN (1 and 2) exons 1, 4, 6 and 8, NAIP 
(BIRC1), GTF2H2 (BTFFp44), RAD17, and CDH6 in the 
5q13 region (16 probes) and several control fragments on 
different chromosomes (21 probes), as well as the standard 
multiple ligation-dependent probe amplification (MLPA) 
control probes used to determine ligation efficiency and 
DNA concentration. Details of probe sequences and gene 
loci are shown on the company’s Web site (http://www.
mrc-holland.com).
MLPA analyses were carried out according to the manu-
facturer’s protocol (MRC Holland). In brief, 50-500 ng of 
DNA was denatured (98°C, 5 min) and hybridized with the 
probe set overnight at 60°C, using the SALSA probe mix. 
Ligation was performed using ligase-65 enzyme at 54°C 
for 15 min. The reactions were inactivated by incubation at 
98°C for 5 min. PCR was performed using the specific 
SALSA PCR primers for 35 cycles (95°C for 30 s; 60°C for 
30 s; 72°C for 1 min) using GeneAmp® PCR System 9700 
(Applied Biosystems Inc., Foster City, CA, USA). The PCR 
products were analyzed in a capillary DNA sequencer (ABI 
PRISM 310 Genetic Analyser, Applied Biosystems) with 
Genescan 3.7 Software (Applied Biosystems). 
Data analysis was performed using the software Gene-
Maker® V 1.60 (SoftGentics, LLC, State College, PA, 
USA). The peak height of each specific probe was normal-
ized by dividing it with the combined heights of the control 
probes. The relative peak height of each probe was com-
pared with the relative peak height of the same probe in the 
control samples. A ratio of under 0.6 was taken as a sign of 
the presence of only one copy of the SMN1 or SMN2 gene.
Statistical analysis
We used SPSS statistical software (version 15, SPSS Inc., 
in 400-700. It has been commonly stated that familial amy-
otrophic lateral sclerosis represents 10% of ALS, of which 
20% is associated with an autosomal dominant mutation in 
the Copper/Zinc superoxide dismutase 1 gene (SOD1).1 
The remaining 90% of cases do not have an obvious family 
history of ALS and appear sporadically. Though the etiolo-
gy of sporadic ALS (sALS) is unknown, epidemiological 
data indicate that sALS is a multifactorial disease in which 
unidentified modifying genetic factors contribute to patho-
genesis.2 Many candidate genes have been implicated, but 
no single gene has been definitely shown to cause sALS un-
til now.3 Humans have two nearly identical copies of SMN 
genes4: SMN1 located in the telomeric region on chromo-
some 5q13 and its centromeric copy, called SMN2. The full-
length survival motor neuron (SMN) protein is encoded al-
most exclusively by SMN1. Conversely, the truncated SMN 
protein encoded by SMN2 lacks the exon 7 sequence and is 
less stable and more easily degraded. SMN is a ubiquitous-
ly expressed housekeeping protein that is essential for cell 
survival. Reduced levels of SMN cause harmful effects ei-
ther to the splicing or to the axonal transport of a limited 
number of target genes that are specific to motor neurons.5 
Homozygous deletion of SMN1 is present in nearly all cases 
of infantile spinal muscular atrophy (SMA). SMN2 is be-
lieved to modulate its phenotype.6 
In this study, we determined SMN1 and SMN2 ratios in a 
small cohort of 25 Korean patients with sALS to investigate 
whether the SMN1 : SMN2 genotype is associated with sus-
ceptibility to and severity of sALS in a Korean population.
MATERIALS AND METHODS
　　　
Subjects
Twenty-five Korean patients were enrolled at the Neuro-
muscular Center of Gangnam Severance Hospital between 
2003 and 2009. All of the patients were over the age of 15. 
They had both upper and lower motor neuron signs without 
any sensory symptoms. They were categorized as having 
definite, probable, or possible ALS according to El Escorial 
criteria.7 The following clinical data were obtained from the 
patients: age at disease onset, duration of disease until diag-
nosis, type of onset (spinal, bulbar), and El Escorial criteria. 
The clinical data were collected before the results of the ge-
netic studies were available. A total of 100 Korean healthy 
individuals who had no family history of motor neuron dis-
order served as controls.8 We collected written informed 
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was lower in the 2 : 0 genotype group (2, 5, 13 and 1 in 2 : 
0, 2 : 1, 2 : 2 and 2 : 3 genotype) (p=0.02).
DISCUSSION
Two previous French studies6,9 showed an increased fre-
quency of homozygous SMN2 deletions in groups with 
ALS. In this study, 20% of the Korean patients (5 out of 25) 
had homozygous deletions of SMN2 as compared to 2% (2 
out of 100) of the healthy controls. 
The relative predominances of male and spinal onset pa-
tients in our study were not significantly different from pre-
vious studies.1,4,10
The SMN protein is a well-documented component of 
the ribonuclear protein complexes required for mRNA tran-
scription, splicing and trafficking.5 It also serves in local 
Chicago, IL, USA). Fisher’s exact test was used to compare 
differences in the proportions of homozygous or heterozy-
gous deletion of SMN between the patient and control groups. 
An ANOVA test was performed to compare differences in 
age of onset and medical research council (MRC) scale 
among the different patient genotypes. Significance was set 
at p<0.05. 
 
RESULTS
 
Table 1 shows the clinical characteristics of the patients ac-
cording to sex, onset age, disease duration, type of onset 
and El Escorial criteria. In the control group, only sex and 
age were shown. There were 14 male and 11 female pa-
tients. The mean age was 52.6±17.3 years and the mean age 
of onset was 49.5±16.4 years. The mean disease duration 
before diagnosis was 3.60±2.74 years. Twenty-two patients 
had spinal onset and three had bulbar onset. According to 
El Escorial criteria, 12 patients were definite, 11 were prob-
able, and two were possible ALS patients.
Table 2 shows SMN1 : SMN2 genotypes between patient 
and control groups. There was higher incidence of 2 : 0 
genotype in patients with sALS (20% in sALS, 2% in con-
trol) (p<0.001). Calculation of total predicted SMN protein 
levels are displayed.
Table 3 shows onset age and initial motor grade in the 
patient group according to SMN1 : SMN2 genotypes. The 
onset age was younger in the 2 : 0 genotypes (34±15.38 
years) than in the other genotypes (58±6.11, 52±14.62 and 
45±7.07 years in 2 : 1, 2 : 2 and 2 : 3 genotypes) (p=0.049). 
The number of patients with an MRC scale higher than G4- 
Table 1. Patient Characteristics
Characteristics Patient Control
Number 25 100
Sex (male/female) 14/11 53/47
Age 52.6±17.3 45.1±7.89
Onset Age 49.5±16.4
Duration of disease 3.60±2.74
Type of onset
    Spinal 22
    Bulbar   3
El Escorial criteria
    Definite 12
    Probable 11
    Possible   2
Continuous data are shown as mean±SD. 
Table 2. SMN1 : SMN2 Genotype in the Control and Patient Groups
SMN1 : SMN2 Control sALS Calculated SMN protein†
1 : 1 1 (1%) 0 1.2
1 : 3 1 (1%) 0 1.6
2 : 0 2 (2%)   5 (20%)‡ 2.0
2 : 1 28 (28%)  6 (24%) 2.2
2 : 2 63 (63%) 13 (52%) 2.4
2 : 3 3 (3%) 1 (4%) 2.6
3 : 2 1 (1%) 0 3.4
2 : 2/3 : 1* 1 (1%) 0 2.4/3.2
Total 100 (100%)   25 (100%)
sALS, sporadic amyotrophic lateral sclerosis; SMN, survival motor neuron gene; SMN1, telomeric survival motor neuron gene; SMN2, 
centromeric survival motor neuron gene.
*Hybrid SMN genes, SMN1 exon 7 : SMN2 exon 7/SMN1 exon 8 : SMN2 exon 8.
†Calculated SMN protein=SMN1 copy number+0.2×SMN2 copy number.
‡p<0.001.
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measure disease severity among different SMN genotypes. 
Regardless of the limitations that have reported that onset 
age depends inevitably on the patient’s memory, the 2 : 0 
genotype group showed a significantly earlier onset age. 
Further objective disease severity scales to match geno-
types should be identified in the future.
In conclusion, our data show that homozygous deletion 
of SMN2 could be one of the risk factors for sALS and cor-
relates with disease severity expressed at a younger onset 
age and a lower MRC scale in the Korean population.
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